泰麟方联合持续低剂量抗菌治疗复发性尿路感染的临床疗效:多中心、双盲、随机、对照临床试验研究方案
复发性尿路感染(rUTI)因抗菌药物耐药(AMR)日益难治,持续低剂量抗生素治疗(CLAT)虽常用但不良反应值得关注。本研究为多中心、双盲、随机、对照试验,拟纳入200例无并发症rUTI患者,按1:1随机分为泰麟方(TLF)联合CLAT组与安慰剂联合CLAT组,治疗12周、随访12周,主要结局为随访第12周复发率,并评估肝肾功能、中医症状、非感染相关体征及主观症状评分、发作次数、生命体征和严重不良事件(SAEs),以评价联合方案的疗效与安全性。
要点
- 多中心双盲随机对照试验,纳入200例无并发症rUTI患者,1:1分为TLF+CLAT组与安慰剂+CLAT组。
- 治疗期12周、治疗后随访12周,主要结局为随访第12周复发率。
- 次要结局包括肝肾功能变化、中医症状、非感染相关体征及主观症状评分、发作次数、生命体征和SAEs。
核心结论
- 本研究旨在提供可信的研究数据,评价TLF联合CLAT治疗rUTI的临床疗效与安全性,并为临床医生提供循证推荐。
研究设计与样本
- 多中心、双盲、随机、对照临床试验,拟纳入200例诊断为无并发症rUTI的合格患者。
- 患者按1:1比例随机分为TLF+CLAT组和安慰剂+CLAT组;试验分两阶段:12周治疗期和12周治疗后随访期。
- 试验注册于中国临床试验注册中心ChiCTR2100041914,注册日期2021年1月10日;方案日期2020年9月12日,版本1。
关键数值与推荐
- 主要结局为随访第12周复发率。
- 次要结局为治疗后肝肾功能变化;对中医症状、非感染相关体征和主观症状进行评分;记录每例受试者发作次数;全程监测生命体征指标和SAEs。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Given the increasing rates of antimicrobial resistance (AMR), recurrent urinary tract infection (rUTI) is becoming refractory more and more. Antibiotic prophylaxis including continuous low-dose antibiotic therapy (CLAT), is the common treatment for rUTI of the world. However, the presumably adverse reactions caused by CLAT alone should be paid more attention. Studies indicated that Chinese herbal medicine (CHM) might be an available treatment method for rUTI. Tailin formulation (TLF) is a herbal prescription developed for the treatment of rUTI in the 2000s in Shanghai Municipal Hospital of Traditional Chinese Medicine. Our previous studies have shown TLF could prevent urinary tract infection both in pyelonephritis (PN) rat model and in PN patients. Additionally, our published data demonstrated TLF is helpful to reduce the recurrence of rUTI and protect renal tubular function in clinic. In order to find a novel treating project for rUTI to increase the clinical curative effect, we thus try to combine TLF with CLAT to treat rUTI and design an optimized, pragmatically clinical trial to evaluate the efficacy and safety of this project. METHODS/DESIGN: This is a multicenter, double-blind, randomized, controlled clinical trial. We will enroll 200 eligible patients diagnosed with uncomplicated rUTI and then divide them randomly into two groups with a 1:1 ratio: TLF + CLAT group and placebo + CLAT group. This trial consists of two stages, a 12-week period of treatment and a 12-week period of post-treatment follow-up, respectively. The primary outcome will be the recurrence rate at the 12th week of the follow-up period; the second outcomes will be the post-treatment changes in renal and liver function; furthermore, traditional Chinese medicine (TCM) symptoms, non-infection-related physical signs, and subjective symptoms will be scored, and the number of episodes of each subject will be also recorded; meanwhile, vital signs indicators and serious adverse events (SAEs) will be monitored throughout the trial. DISCUSSION: This study will provide convictive research-derived data to evaluate clinical efficacy and safety of TLF combined with CLAT for rUTI, and provide an evidence-based recommendation for clinicians. Moreover, post-treatment changes in non-infection-related physical signs and subjective symptoms were included in the efficacy evaluation, which is important and more significant for assessing the clinical benefits for those rUTI patients. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100041914 . Registered on 10 January 2021. Protocol date and version: September 12, 2020; version 1.
引用
- Li T, Xu Y, Gong X, et al. Clinical efficacy of Tailin formulation combined with continuous low-dose antimicrobial therapy for recurrent urinary tract infection: study protocol for a multicenter, double-blind, randomized, controlled clinical trial. Trials. 2021. PMID: 34895307. doi:10.1186/s13063-021-05830-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。